Mroz Andrzej, Kiedrowski Miroslaw, Lewandowski Zbigniew
Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Medical University of Warsaw, Warsaw, Poland.
Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):313-7. doi: 10.1097/PAI.0b013e318268d034.
Diagnostic and prognostic significance of α-methylacyl-CoA racemase (AMACR) has been established in many human cancers. Its correlation with clinical and pathologic data in gastric cancer has not been fully elucidated and its impact on surveillance has not been studied thus far. We analyzed consecutive gastric cancer cases in terms of AMACR expression and clinical/pathologic characteristics and followed patients' postoperative history. AMACR was expressed in 94/164 gastric cancers (57.3%). We did not find correlation between AMACR expression and sex, age, location, histologic type, pTN staging, vascular and nerve sheaths invasion. Overall disease-free survival tended to be worse in AMACR-positive patients (P=0.062), and in adenocarcinoma subgroup, it was significantly shorter (P=0.021). AMACR expression might represent promising adverse prognostic factor in gastric cancer, particularly in adenocarcinoma histologic type.
α-甲基酰基辅酶A消旋酶（AMACR）在多种人类癌症中的诊断和预后意义已得到确立。其与胃癌临床及病理数据的相关性尚未完全阐明，迄今为止其对监测的影响也未得到研究。我们根据AMACR表达及临床/病理特征分析了连续的胃癌病例，并随访了患者的术后病史。164例胃癌中有94例（57.3%）表达AMACR。我们未发现AMACR表达与性别、年龄、部位、组织学类型、pTN分期、血管及神经鞘侵犯之间存在相关性。AMACR阳性患者的总体无病生存期往往较差（P = 0.062），在腺癌亚组中，其无病生存期显著更短（P = 0.021）。AMACR表达可能是胃癌，尤其是腺癌组织学类型中有前景的不良预后因素。
Zotero 插件